Novo expects to continue to grow its reach in 2025, though perhaps not at the magnitude witnessed in 2024. For the full year to come, Novo Nordisk is eyeing sales growth at constant currencies between ...

If California patients pay more than $35 per month for insulin now, it’s in large part because PBMs have rigged the system in ...

Minnesota announced a final settlement Monday with the last of three manufacturers of insulin, who agreed to cap insulin prices for the next five years. (Jeff Wheeler/The Minnesota Star Tribune) ...

Minnesota A.G. Keith Ellison says his office settled with Novo Nordisk to cap monthly out-of-pocket payments for insulin at $35 a month.

Both companies could launch their first GLP-1 products as early as 2028, potentially making them strong competitors to current market leaders, Novo Nordisk ... such as Type 2 diabetes, may accept ...

In a report released today, Jo Walton from UBS maintained a Buy rating on Novo Nordisk (0QIU – Research Report), with a price target of ...

Compounding pharmacies aren’t the only makers of off-brand versions of Novo Nordisk’s Wegovy and Eli Lilly’s Zepbound. The ...

Weight loss treatments Mounjaro and Zepbound are the primary growth engines for Eli Lilly right now, but the company has another enormous opportunity that's getting very little attention.

The former Big Brother UK star, who appeared in season 7 ... Ozempic is an FDA-approved prescription medication to treat type 2 diabetes. The medication — taken weekly by injection in the thigh, ...